Every decision in new drug development ultimately comes back to a single patient. We prioritize patient safety and benefit over speed, cost, and our own performance.

Every decision in drug development ultimately returns to a single patient. We place their safety and benefit above speed, cost, and our own ambition.

We want our drug to be effective for patients more than anyone else. However, hope is not proof. Even when the results disappoint us, let the data decide.

No one hopes more than we do that our medicine helps patients—but hope is not proof. Even when the result disappoints us, we let the data decide.

Efficacy gives the drug an opportunity to reach the patient, and safety preserves that opportunity. We confront risks as they are, without downplaying them.

Efficacy earns a medicine its chance to reach patients; safety protects that chance. We never minimize risk—we face it as it is.

We don't just stop at symptomatic relief; we aim for root cause treatment that changes the course of the disease from its origin. It's a more difficult and longer path, but we believe it's the true way to heal.

We do not settle for symptomatic care that merely eases the surface. We pursue treatment that reaches the root where disease begins and changes its course. It is the harder, longer path—but we believe it is what real treatment means.

A single new drug contains decades of time and countless failures. We measure ourselves not by quarters, but by perseverance and resilience, and we never give up.

A single medicine holds within it a decade and countless failures. We measure ourselves not in quarters but in patience and resilience—and we never give up.